110 related articles for article (PubMed ID: 36854517)
1. 5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells.
Nadai T; Narumi K; Mukai Y; Ueda H; Furugen A; Saito Y; Kobayashi M
Anticancer Res; 2023 Mar; 43(3):1113-1120. PubMed ID: 36854517
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Nadai T; Narumi K; Furugen A; Saito Y; Iseki K; Kobayashi M
Biol Pharm Bull; 2021; 44(9):1247-1253. PubMed ID: 34471053
[TBL] [Abstract][Full Text] [Related]
3. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells.
Yaacob NS; Ismail NF
BMC Complement Altern Med; 2014 Mar; 14():106. PubMed ID: 24646375
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
6. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
7. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
8. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.
Lin HY; Han HW; Wang YS; He DL; Sun WX; Feng L; Wen ZL; Yang MK; Lu GH; Wang XM; Qi JL; Yang YH
Chin Med; 2020; 15():23. PubMed ID: 32175001
[TBL] [Abstract][Full Text] [Related]
9. Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment.
Nishimoto K; Okahashi N; Maruyama M; Izumi Y; Nakatani K; Ito Y; Iida J; Bamba T; Matsuda F
Sci Rep; 2023 Oct; 13(1):18549. PubMed ID: 37899460
[TBL] [Abstract][Full Text] [Related]
10. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.
Steifensand F; Gallwas J; Bauerschmitz G; Gründker C
Cells; 2021 Sep; 10(9):. PubMed ID: 34572047
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
[TBL] [Abstract][Full Text] [Related]
13. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance.
Samaddar JS; Gaddy VT; Duplantier J; Thandavan SP; Shah M; Smith MJ; Browning D; Rawson J; Smith SB; Barrett JT; Schoenlein PV
Mol Cancer Ther; 2008 Sep; 7(9):2977-87. PubMed ID: 18790778
[TBL] [Abstract][Full Text] [Related]
14. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
15. Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
Li Y; Zhang Y; Liu X; Wang M; Wang P; Yang J; Zhang S
Int J Oncol; 2018 Jun; 52(6):2119-2129. PubMed ID: 29620169
[TBL] [Abstract][Full Text] [Related]
16. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
18. Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade.
Rabenoelina F; Semlali A; Duchesne MJ; Freiss G; Pons M; Badia E
Int J Cancer; 2002 Apr; 98(5):698-706. PubMed ID: 11920638
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
20. Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.
Badia E; Morena M; Lauret C; Boulahtouf A; Boulle N; Cavaillès V; Balaguer P; Cristol JP
Breast Cancer; 2016 Sep; 23(5):692-700. PubMed ID: 26193841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
